A Phase 2 clinical trial for once daily oral testosterone undecanoate for the treatment of male hypogonadism.
Latest Information Update: 22 May 2022
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Clarus Therapeutics
- 22 May 2022 New trial record
- 16 May 2022 According to a Clarus Therapeutics media release, this trial is expected to be initiated in the second half of 2022, subject to availability of funding